Want to see LUCD full AI Analyst Report?
LUCD Stock Chart & Stats
$0.97
<$0.01(0.26%)
At close: 4:00 PM EDT
$0.97
<$0.01(0.26%)
Day’s Range― - ―
52-Week Range$0.30 - $1.63
Previous CloseN/A
Volume689.08K
Average Volume (3M)2.87M
Market Cap
$83.53M
Enterprise Value$187.45M
Total Cash (Recent Filing)$33.40M
Total Debt (Recent Filing)$24.91M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Nov 16, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding203,243,970
10 Day Avg. Volume5,172,763
30 Day Avg. Volume2,871,466
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.16
Price to Sales (P/S)23.61
P/FCF Ratio-2.39
Enterprise Value/Market Cap2.24
Enterprise Value/Revenue34.43
Enterprise Value/Gross Profit-133.51
Enterprise Value/Ebitda-3.65
Forecast
1Y Price Target
$4.00Price Target Upside312.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$6.31M
Bulls Say, Bears Say
Bulls Say
Revenue And Test-volume GrowthRevenue and test volume are moving upward, indicating expanding utilization of EsoGuard and a developing commercial base. Continued growth in testing activity can improve operating leverage over time, provided Lucid converts billable volume into collected reimbursement.
Reimbursement And Coding InfrastructureProgress on Medicare payment pathways and dedicated procedure and diagnosis coding strengthens the infrastructure needed for routine clinical use. Better coding can improve claim submission, documentation, utilization tracking, and payer acceptance across Lucid’s addressable market.
Potentially High Test-level MarginsThe cited cost structure suggests substantial gross-margin potential once reimbursement is established and testing volume scales. High incremental economics could allow future revenue growth to translate into stronger contribution margins, although the benefit depends on actual payment realization.
Bears Say
Persistent Operating Losses And Cash BurnLarge operating and free-cash-flow deficits show that the current revenue base does not fund the business. Continued cash consumption raises the need for external financing and leaves less flexibility to invest in commercialization, absorb reimbursement delays, or reach profitability.
Weak Reimbursement ConversionThe gap between billable test value and recognized revenue demonstrates that utilization is not yet translating reliably into cash-generating sales. Pending Medicare coverage and claim uncertainty could prolong collection cycles and constrain revenue visibility during the commercialization period.
Dilutive And Costly Financing StructureThe new preferred financing improves liquidity but adds a senior claim, a substantial dividend obligation, and conversion exposure that can increase dilution. Combined with existing secured convertible debt, these terms may absorb future cash and restrict capital-allocation flexibility.
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics’s price range in the past 12 months?
Lucid Diagnostics lowest stock price was $0.30 and its highest was $1.63 in the past 12 months.
What is Lucid Diagnostics’s market cap?
Lucid Diagnostics’s market cap is $83.53M.
When is Lucid Diagnostics’s upcoming earnings report date?
Lucid Diagnostics’s upcoming earnings report date is Nov 16, 2026 which is in 22 days.
How were Lucid Diagnostics’s earnings last quarter?
Lucid Diagnostics released its earnings results on Aug 13, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.057 by -$0.003.
Is Lucid Diagnostics overvalued?
According to Wall Street analysts Lucid Diagnostics’s price is currently Undervalued.
Does Lucid Diagnostics pay dividends?
Lucid Diagnostics does not currently pay dividends.
What is Lucid Diagnostics’s EPS estimate?
Lucid Diagnostics’s EPS estimate is -0.06.
How many shares outstanding does Lucid Diagnostics have?
Lucid Diagnostics has 203,243,970 shares outstanding.
What happened to Lucid Diagnostics’s price movement after its last earnings report?
Lucid Diagnostics reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.057. Following the earnings report the stock price went down -2.033%.
Which hedge fund is a major shareholder of Lucid Diagnostics?
Currently, no hedge funds are holding shares in LUCD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (312.37% Upside)
$4.00 (312.37% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 29.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.5%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.58%
12-Months-Change
Fundamentals
Return on Equity
-404.34%
Trailing 12-Months
Asset Growth
0.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
LUCD Company Deck
LUCD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful commercial and market-access progress—most notably the first LBM coverage policy from Concert, encouraging preliminary HEOR results, targeted test volumes within guidance, and a successful $16.8M equity raise—while simultaneously highlighting persistent reimbursement and collection challenges (pending Medicare LCD, low near-term revenue capture of billable tests, adjudication/denial rates), a sustained quarterly cash burn (~$11.3M), and financing obligations. Achievements on coverage, HEOR, and health system engagement materially de‑risk the commercial pathway over time, but near-term financial performance remains constrained by reimbursement timing and claim collection dynamics.View all LUCD earnings summariesLUCD Stock 12 Month Forecast
Average Price Target
$4.00
▲(312.37% Upside)
Technical Analysis
Ownership Overview
5.36% Insiders
3.77% Mutual Funds
3.03% Other Institutional Investors
81.59% Public Companies and
Individual Investors